Dipeptidyl Peptidase-4 Inhibitors Have Protective Effect on Cognitive Impairment in Aged Diabetic Patients With Mild Cognitive Impairment
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Older adults with type 2 diabetes have an increased risk for mild and severe cognitive impairment probably as consequence of chronic hyperglycemia or fasting plasma glucose levels. Variability in glucose level and recurrent hypoglycemic episodes are also associated with cognitive impairment. Dipeptidyl peptidase-4 inhibitor (DPP-4I) therapy affects glycemic variability. The purpose of this study was to evaluate the effect of DPP-4I therapy on changes in cognitive function in older patients with type 2 diabetes complicated by mild cognitive impairment. METHODS: This retrospective longitudinal study used data from a database of 240 older patients with type 2 diabetes, "drug naive," affected by mild cognitive impairment, subsequently treated for 2 years with antidiabetic drugs (DPP-4I group: DPP-4I + metformin, n = 120; SU group: sulfonylurea + metformin, n = 120) and reassessed in our ambulatory by comprehensive clinical, cognitive, instrumental examinations, and continuous subcutaneous glucose monitoring. RESULTS: At baseline, larger mean amplitude of glycemic excursion values correlated with poorer Mini-Mental State Examination and composite cognitive function scores. We found that higher body mass index, higher 2-hour postprandial glucose, and greater mean amplitude of glycemic excursion values measured at baseline were significant independent predictors of cognitive worsening. In addition, reduction in mean amplitude of glycemic excursions and the use of DPP-4I therapy predicted improvement in cognitive functions. CONCLUSIONS: In older patients with type 2 diabetes affected by mild cognitive impairment, DPP-4I administration improves glucose control and protects against worsening in cognitive functioning.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk of dementia in diabetes mellitus: a systematic review
Biessels, G. J., Staekenborg, S., Brunner, E., Brayne, C., & Scheltens, P. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(05)70284-2 · Cited by 2,187
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Launer, L. J., Miller, M. E., Williamson, J. D., Lazar, R. M., Gerstein, H. C., Murray, A. M., Sullivan, M., Horowitz, K. R., Ding, J., Marcovina, S., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70188-0 · Cited by 574
Diabetes in Older Adults: A Consensus Report
Sue Kirkman, M., Briscoe, V. J., Clark, N., Florez, H., Haas, L. B., Halter, J. B., Huang, E. S., Korytkowski, M. T., Munshi, M. N., Odegard, P. S., et al. (2012) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12035 · Cited by 548
Sinclair, A., Morley, J. E., Rodriguez-Mañas, L., Paolisso, G., Bayer, T., Zeyfang, A., Bourdel-Marchasson, I., Vischer, U., Woo, J., Chapman, I., et al. (2012) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2012.04.012 · Cited by 422
Self-citationDiabetes, glucose control, and 9-year cognitive decline among older adults without dementia
Yaffe, K., Falvey, C., Hamilton, N., Schwartz, A. V., Simonsick, E. M., Satterfield, S., Cauley, J. A., Rosano, C., Launer, L. J., Strotmeyer, E. S., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.1117 · Cited by 313
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204
Perry, T., & Greig, N. (2005) · Current Alzheimer Research · doi:10.2174/1567205054367892 · Cited by 127
Holscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102
Abbatecola, A. M., Lattanzio, F., Molinari, A. M., Cioffi, M., Mansi, L., Rambaldi, P., DiCioccio, L., Cacciapuoti, F., Canonico, R., & Paolisso, G. (2010) · Diabetes Care · doi:10.2337/dc09-2030 · Cited by 93
Self-citation
Cited by
Antidiabetic agents as a novel treatment for Alzheimer’s and Parkinson’s disease
Nowell, J., Blunt, E., Gupta, D., & Edison, P. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101979 · Cited by 179
“DPP-IV inhibitors have demonstrated efficacy in protecting cognitive function in elderly patients with mild cognitive impairment (Rizzo et al., 2014) and AD (Isik et al., 2017).”
BackgroundMethodGlycemic variability: how to measure and its clinical implication for type 2 diabetes
Umpierrez, G. E., & P. Kovatchev, B. (2018) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2018.09.010 · Cited by 148
Reading, C. L., Ahlem, C. N., & Murphy, M. F. (2021) · Neurodegenerative Disease Management · doi:10.2217/nmt-2021-0022 · Cited by 84
Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
Sim, A. Y., Barua, S., Kim, J. Y., Lee, Y.-H., & Lee, J. E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708547 · Cited by 62
Wu, J., Zhou, S.-L., Pi, L.-H., Shi, X.-J., Ma, L.-R., Chen, Z., Qu, M.-L., Li, X., Nie, S.-D., Liao, D.-F., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17257 · Cited by 50
Metadata
- Authors
- Rizzo, M. R., Barbieri, M., Boccardi, V., Angellotti, E., Marfella, R., & Paolisso, G.
- Venue
- The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-03-26
- Volume
- 69
- Issue
- 9
- Pages
- 1122-1131
- ISSN
- 1079-5006 (ISSN-L)
- 1758-535X
- OpenAlex
- W2118119265
- Cited by
- 105
- References
- 10
- FWCI
- 3.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.